Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Tech medical study

Menopause Hormone Therapy Heart Risk Study

Analysis based on 9 articles · First reported Sep 08, 2026 · Last updated Sep 11, 2026

Sentiment
5
Attention
2
Articles
9
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

The study may modestly support demand for menopause hormone therapy products by reinforcing a more favorable cardiovascular safety narrative for early initiation, a positive for makers of estrogen therapies. However, the authors' explicit caution against using hormone therapy for heart prevention and the observational design limit any near-term change to prescribing guidelines or revenue forecasts.

pharmaceuticals healthcare insurance

A new observational analysis published in JAMA Internal Medicine on Sept. 8, 2026, reports that women with vasomotor symptoms (hot flashes and night sweats) who started menopause hormone therapy during perimenopause or early postmenopause had a 22% lower risk of cardiovascular events than similar women who did not start treatment. The study was led by researchers at Virginia Commonwealth University and the University of Pittsburgh, using roughly 20 years of data (1997-2017) from more than 2,700 participants in the Study of Women's Health Across the Nation (SWAN), funded by the United States — National Institutes of Health. The apparent benefit was strongest among women who began therapy within 10 years of menopause onset (about 27% lower risk) and among Black women (about 49% lower risk). No clear benefit was seen for women starting more than 10 years after menopause or for White women and other racial and ethnic groups. The authors cautioned that the study was not a randomized trial and that findings should not be used to prescribe hormone therapy for cardiovascular prevention. The results arrive as the United States — Food and Drug Administration has removed broad boxed warnings from hormone therapy products, reflecting evolving evidence. Lead author Ziyuan Wang is now at Eli Lilly and Company, and independent expert Stephanie Luo of Northwell Health commented on the findings, emphasizing individualized care.

60 United States — Food and Drug Administration removed black-box warnings
10 Eli Lilly and Company hired researcher Ziyuan Wang
per
Senior author and VCU epidemiologist who led the analysis and emphasized that timing of hormone therapy initiation may influence cardiovascular outcomes.
Importance 75.0 Sentiment 0.0
per
Senior author from the University of Pittsburgh who cautioned that the observational findings should not guide clinical practice.
Importance 70.0 Sentiment 0.0
govactor
Its 2026 removal of boxed warnings from hormone therapy products is cited as context; the study may reinforce the regulatory shift.
Importance 45.0 Sentiment 5.0
govactor
Funded the SWAN study that provided the data; the findings may inform future NIH-funded research priorities.
Importance 40.0 Sentiment 0.0
per
Independent expert from Northwell Health who reviewed the findings and stressed individualized care and the importance of timing.
Importance 30.0 Sentiment 0.0
per
Lead author of the study, now working in pharmacoepidemiology at Eli Lilly and Company.
Importance 25.0 Sentiment 0.0
cnt
The study is a U.S.-based analysis of American women, and the FDA's regulatory shift affects U.S. hormone therapy use.
Importance 20.0 Sentiment 0.0
stock
Lead author Ziyuan Wang now works in pharmacoepidemiology at Eli Lilly, a minor disclosure link to the study.
Importance 15.0 Sentiment 0.0
ngo
Its Katz Institute for Women's Health provided independent expert commentary through Dr. Stephanie Luo.
Importance 15.0 Sentiment 0.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.